J B Chemicals & Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• J B Chemicals & Pharmaceuticals Ltd reported a 15.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 5.0%.
• Its expenses for the quarter were down by 7.6% QoQ and 2.2% YoY.
• The net profit decreased 48.8% QoQ and decreased 30.4% YoY.
• The earnings per share (EPS) of J B Chemicals & Pharmaceuticals Ltd stood at 6.32 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

J B Chemicals & Pharmaceuticals Ltd is a prominent entity in the pharmaceutical industry, known for its production and marketing of a wide range of pharmaceutical formulations, including tablets, ointments, injectables, and liquid formulations. The company has a global footprint with a focus on both domestic and international markets. Its product range caters to various therapeutic segments such as cardiology, gastroenterology, and anti-infectives. As of the last known updates, the company has been focusing on expanding its market presence and enhancing its product portfolio through strategic initiatives. However, specific recent developments within the company are not available at this time.

Revenue

In the fourth quarter of FY26, J B Chemicals & Pharmaceuticals Ltd reported a total income of ₹916.21 crores. This represents a decline of 15.4% quarter-over-quarter (QoQ) from ₹1,083.00 crores reported in Q3FY26. When compared to the same quarter in the previous fiscal year (Q4FY25), where the total income was ₹963.96 crores, there is a year-over-year (YoY) decrease of 5.0%. This decrease in total income both QoQ and YoY signals changes in revenue generation during this period.

Profitability

For the Q4FY26, the company recorded a profit before tax (PBT) of ₹134.69 crores, which is a significant decline of 49.5% QoQ from ₹266.87 crores in Q3FY26. Comparatively, in Q4FY25, the PBT was ₹193.03 crores, indicating a YoY decrease of 30.2%. The tax expense for Q4FY26 was ₹33.32 crores, down by 51.7% from Q3FY26 and 29.6% from Q4FY25. Consequently, the profit after tax (PAT) for Q4FY26 stood at ₹101.37 crores, marking a 48.8% decrease QoQ and a 30.4% decrease YoY. The earnings per share (EPS) for Q4FY26 was ₹6.32, which is a decline of 49.2% from the previous quarter and 31.1% from the same quarter last year.

Operating Metrics

The total expenses for Q4FY26 were ₹754.34 crores, showing a reduction of 7.6% from Q3FY26, where expenses were ₹816.13 crores. Compared to Q4FY25, total expenses decreased by 2.2% from ₹770.93 crores. These figures reflect the company's operational spending trends over the analyzed periods. The decrease in expenses QoQ and YoY is a notable aspect of the company's financial operations. The current data does not provide specific financial ratios such as P/E ratio, debt-to-equity ratio, or current ratio, nor does it include detailed operational metrics beyond the financial figures mentioned.